Oxford Science Enterprises

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

Iota Sciences Ltd. is a company focused on developing tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. Founded in 2016 and headquartered in Oxford, United Kingdom, the company specializes in creating fluidic mu-wells specifically designed for cell biology applications. Through its innovative approach, Iota Sciences aims to provide unique capabilities that facilitate advancements in the understanding and manipulation of cellular processes, thereby accelerating research and development in the pharmaceutical sector.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Sitryx Therapeutics is a biopharmaceutical company based in Oxford, United Kingdom, established in 2018. The company specializes in developing disease-modifying therapeutics that target immuno-oncology and immuno-inflammation by regulating cell metabolism. Through its innovative approach, Sitryx aims to correct and alter immune cell functions to inhibit tumor growth. Co-founded by a team of renowned scientists from both the United States and Europe, Sitryx is committed to advancing the field of immunometabolism. The company has a diverse pipeline of projects at various stages of drug discovery, supported by significant investments from a syndicate of specialist investors.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

Nucleome Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, founded in 2019. The company focuses on decoding the "dark matter" of the human genome, which comprises over 95% of disease-linked genetic variants that have not yet been fully explored. By leveraging a unique platform that creates high-resolution three-dimensional genome structure maps and employs machine learning techniques, Nucleome aims to link these genetic variants to gene functions and map disease pathways. This innovative approach facilitates the functional validation of variants in primary cell types, enabling the discovery and development of novel therapeutics. Initially concentrating on lymphocytes and autoimmune diseases, Nucleome Therapeutics seeks to establish a robust pipeline of drug assets along with corresponding biomarkers to improve patient outcomes through genetically guided therapeutics.

Opsydia Limited, established in 2017 and based in Begbroke, UK, specializes in manufacturing advanced laser marking technology. This technology enables the creation of permanent, invisible structures such as serial numbers, images, and cryptographic data within transparent materials like diamonds, glass, polymers, and plastics without altering their surface or integrity. Opsydia's innovative solution aims to disrupt various industries by enhancing security, traceability, and authenticity in transparent materials.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Orbit Discovery is a biotechnology company specializing in peptide display technology to identify potential peptide drugs for chronic diseases. Its proprietary Orbit platform uses small beads linked with randomized peptide sequences to DNA, enabling screening tools for various disease types. The company focuses on establishing collaborative research platforms and internal drug discovery programs.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

SpyBiotech Limited is a biotechnology company headquartered in Oxford, United Kingdom, founded in 2017. It develops a proprietary protein superglue technology that bonds antigens to viral or other particle carriers, creating what the company calls bonding vaccines. This platform enables research institutions and medical facilities to design and produce vaccines against infectious diseases and cancer more rapidly and with potentially improved efficacy. By simplifying the assembly of vaccine components, SpyBiotech aims to accelerate the development cycle and reduce time to clinical application.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Living Optics designs and develops a compact hyperspectral imaging camera and accompanying software to provide spectral imaging data across industrial, consumer, medical, and manufacturing applications. The system captures information beyond the capabilities of ordinary cameras, delivering accessible, portable hyperspectral imaging for use in research and product development. The company was founded in 2019 and is based in Oxford, United Kingdom.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Refeyn Ltd develops and commercializes mass photometry technology for measuring the mass of single biomolecules in solution. The company offers instruments and accessories, including Refeyn One, which uses single-molecule light scattering to detect, image, and determine the mass of biomolecules in their native, unlabeled state. Its technology provides both research-grade tools and quality-control instruments for measuring biomolecules across a range of concentrations, enabling label-free mass measurement of individual molecules. Founded in 2018 and based in Oxford, United Kingdom, Refeyn focuses on delivering precise, rapid mass analysis to researchers studying proteins, nucleic acids, and other biomolecules.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Living Optics designs and develops a compact hyperspectral imaging camera and accompanying software to provide spectral imaging data across industrial, consumer, medical, and manufacturing applications. The system captures information beyond the capabilities of ordinary cameras, delivering accessible, portable hyperspectral imaging for use in research and product development. The company was founded in 2019 and is based in Oxford, United Kingdom.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

MiroBio Ltd is a biotechnology company based in Oxford, United Kingdom, focused on the development and manufacture of antibody modulators for immune cell receptors, targeting autoimmune diseases. Established in 2018, MiroBio leverages groundbreaking research from the University of Oxford to understand the communication and activation mechanisms of immune cells. The company's innovative platform aims to create antibodies that stimulate specific immune signals, harnessing the body's natural control mechanisms to restore balance within the immune system. By activating these natural processes, MiroBio seeks to provide significant therapeutic benefits for patients suffering from a range of autoimmune conditions, enabling clinicians to better manage and treat these diseases.

MoA Technology Ltd. is a plant genetics company based in Leeds, United Kingdom, that was spun out from the University of Oxford in 2017. The company focuses on developing innovative agricultural technologies aimed at enhancing sustainable crop systems. Led by Professor Liam Dolan, FRS, MoA Technology employs a unique approach to facilitate the production of healthy food, thereby supporting farmers in their efforts to cultivate crops sustainably.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Founded in 2018 as a spin-out from the University of Oxford, Caristo Diagnostics develops artificial intelligence-based software for measuring coronary artery inflammation to predict heart attacks. Its flagship product, CaRi-Heart, applies advanced AI algorithms to routine cardiac CT scans, visualizing and quantifying coronary inflammation, which is the root cause of coronary artery disease. The company's patented Fat Attenuation Index (FAI) biomarker indicates a patient's risk relative to peers, while CaRi-Heart Risk assesses absolute 8-year fatal heart attack risk. Caristo Diagnostics has attracted over £23 million in venture capital investment and its technology is CE Mark certified.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

BioBeats, established in 2012 and headquartered in London, specializes in digital health solutions for personal wellness. The company leverages artificial intelligence and real-time data from smartphones and wearables to tackle global mental health challenges. By fusing research from the University of Oxford, BioBeats creates AI products that track neurological and physiological correlates to psychological progress, predict disorder onset, and provide personalized support. Their psychological wellness application calculates a baseline wellbeing score and offers insights into stress responses, enabling users to identify harmful patterns and improve their overall mental health.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Opsydia Limited, established in 2017 and based in Begbroke, UK, specializes in manufacturing advanced laser marking technology. This technology enables the creation of permanent, invisible structures such as serial numbers, images, and cryptographic data within transparent materials like diamonds, glass, polymers, and plastics without altering their surface or integrity. Opsydia's innovative solution aims to disrupt various industries by enhancing security, traceability, and authenticity in transparent materials.

Orbit Discovery is a biotechnology company specializing in peptide display technology to identify potential peptide drugs for chronic diseases. Its proprietary Orbit platform uses small beads linked with randomized peptide sequences to DNA, enabling screening tools for various disease types. The company focuses on establishing collaborative research platforms and internal drug discovery programs.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

PQShield specializes in post-quantum cryptography solutions, safeguarding global technology infrastructures against future quantum computing threats. Founded in 2018 and based in Oxford, UK, the company offers hardware, software, and cloud-based implementations, leading standardization efforts worldwide.

Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.

Xerion Healthcare Limited is a biotechnology company based in Thame, United Kingdom, specializing in the development and commercialization of nanoparticle treatments for cancer. Founded in 2015, the company focuses on enhancing the efficacy of conventional radiotherapy by utilizing nanoparticles made from titanium dioxide, a non-toxic semiconductor material. These nanoparticles are injected into tumors prior to standard radiotherapy, where they amplify the generation of free radicals produced by X-rays, thereby improving treatment outcomes. Xerion Healthcare is particularly concentrated on developing its innovative technology for head, neck, and pancreatic cancers, aiming to provide more effective therapies while minimizing side effects for patients.

Latent Logic, acquired by Waymo in December 2019, is a technology company specializing in advanced machine learning techniques aimed at enhancing autonomous vehicles and traffic modeling. Originating from Oxford University’s renowned machine learning department, it focuses on deep reinforcement learning, which enables robots to learn complex tasks through demonstration. By combining computer vision with learning from demonstration, Latent Logic develops realistic road-user models that improve the performance and safety of autonomous control systems. Its technology supports the creation of sophisticated driving simulators, facilitating the rapid development and testing of autonomous vehicles. As Waymo's first engineering hub outside the United States, Latent Logic plays a crucial role in advancing the capabilities of self-driving technologies.

Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.

PepGen Ltd. is a clinical-stage biotechnology company based in Oxford, United Kingdom, focused on advancing the next generation of nucleic acid therapeutics, particularly in the treatment of severe neuromuscular and neurologic diseases. Incorporated in 2018, PepGen has developed its Enhanced Delivery Oligonucleotide (EDO) platform, which is designed to improve the uptake and activity of conjugated oligonucleotide therapeutics. The company's innovative EDO peptides enhance tissue penetration, cellular uptake, and nuclear delivery, demonstrating their ability to transport oligonucleotides effectively into various target tissues, including smooth, skeletal, and cardiac muscle, as well as the central nervous system. PepGen aims to unlock the clinical potential of these transformative therapeutics, with a particular emphasis on the effective delivery of antisense oligonucleotides, and is advancing its novel conjugate therapeutics toward clinical application.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

First Light Fusion Limited is a UK-based company that specializes in researching advanced implosion processes aimed at electricity generation through inertial confinement fusion. Founded in 2011 as a spin-out from the University of Oxford, the company focuses on harnessing fundamental physics to explore various innovative energy generation methods. It employs a team of engineers and physicists who engage in theoretical analysis, detailed numerical simulations, and experimental validation to develop new energy sources. First Light Fusion collaborates closely with several academic institutions, including the University of Oxford, Warwick University, University College London, and Imperial College London. The company, originally named Oxyntix Ltd., rebranded in June 2014 to reflect its focus on fusion energy research.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Alloyed specializes in the research, development, and application of advanced metallic alloys. Founded in 2017 and headquartered in Begbroke, UK, the company focuses on creating optimized alloys and proprietary software for various industries including aerospace, automotive, defense, medical devices, energy, and consumer goods.

Zegami Limited is a company that specializes in visual data exploration, offering a platform designed to assist in analyzing both scientific and medical imaging. Founded in 2015 and headquartered in Oxford, United Kingdom, Zegami's solution integrates media, data, and artificial intelligence to transform visual data into actionable information. The platform enables users to efficiently search, sort, filter, and group large collections of images and associated metadata in real time, facilitating the identification of patterns, correlations, and anomalies within the data. Its applications span various fields, including heating, ventilation, and air conditioning management, microscopy, genomics, plant phenotyping, and cultural heritage institutions such as galleries and museums. Additionally, Zegami's plugin API allows developers to create custom visualizations, enhancing the versatility of their offerings.

DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Ultromics Limited, founded in 2017 and based in Oxford, United Kingdom, specializes in developing advanced echocardiography software aimed at enhancing the diagnosis of coronary heart disease. By leveraging artificial intelligence, the company has created highly accurate diagnostic tools that improve the identification of coronary artery disease, achieving diagnostic accuracy improvements of over 90%. Ultromics' technology processes complex data from electrocardiograms, empowering healthcare providers to make informed clinical decisions and ultimately enhancing patient care in cardiology.

SpyBiotech Limited is a biotechnology company headquartered in Oxford, United Kingdom, founded in 2017. It develops a proprietary protein superglue technology that bonds antigens to viral or other particle carriers, creating what the company calls bonding vaccines. This platform enables research institutions and medical facilities to design and produce vaccines against infectious diseases and cancer more rapidly and with potentially improved efficacy. By simplifying the assembly of vaccine components, SpyBiotech aims to accelerate the development cycle and reduce time to clinical application.

Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.

BibliU operates a digital platform that provides colleges and universities with managed access to millions of textbooks and academic resources. It offers automation tools, analytics, and offline support, enhancing student learning efficiency.

Covatic develops broadcast personalization software and a consumer insights platform that enables on-device personalization for applications. Incorporated in 2016, the company is based in Birmingham, United Kingdom, with an additional office in London. Its platform provides an on-device software development kit that leverages trusted first-party and offline consented data to create contextual audience segments, helping media companies deliver relevant advertising while strengthening user trust and complying with privacy regulations.

Oxford VR Limited is a company that specializes in developing cognitive treatments for clinical conditions utilizing virtual reality technology. Founded in 2016 and based in Oxford, United Kingdom, it emerged as a spin-out from Oxford University, building on the research of Professor Daniel Freeman. The company offers automated treatments delivered by a virtual coach, targeting conditions such as fear of heights, psychosis, and social anxiety. By leveraging immersive virtual reality, Oxford VR aims to provide faster and more effective therapies at a lower cost to health providers. The treatments are designed to be user-centered and clinically validated, thereby enhancing access to mental health care while significantly impacting patients and the broader healthcare system.

EnzBond Ltd is a biotechnology company based in Oxford, United Kingdom, focused on revolutionizing the field of biocatalysis. Established in 2016, the company has developed an automated in silico platform designed for the rapid optimization of enzymes used in the production of small molecules. This proprietary technology significantly reduces enzyme discovery costs by over tenfold compared to leading competitors and accelerates the discovery timeline to mere days. EnzBond's platform excels in predicting enzyme activity with high accuracy and efficiency, allowing for the screening of thousands of enzyme mutants regardless of their sequence, structure, or catalytic characteristics. This innovative approach positions EnzBond at the forefront of biocatalyst optimization for the chemical industry.

DJS Antibodies Ltd is a biotechnology company based in Bicester, United Kingdom, established in 2014. The company focuses on the design and discovery of novel therapeutic monoclonal antibodies specifically targeting G-protein-coupled receptors (GPCRs). DJS Antibodies aims to develop innovative therapeutics for chronic inflammatory diseases by utilizing its advanced technology to create first-in-class antibody therapeutics for previously challenging disease targets. By specializing in the research and discovery of functional antibodies against complex protein targets that have eluded traditional drug discovery efforts, DJS Antibodies endeavors to provide effective treatments for diseases that are currently considered undruggable and untreatable.

Argonaut Therapeutics Limited is a precision therapeutics company based in Oxford, United Kingdom, founded in 2016. The company focuses on developing innovative epigenetically acting drugs aimed at treating cancer by targeting abnormal arginine methylation. Argonaut's therapies are designed to reprogram cancer cells, encouraging them to undergo the body's natural process of cell death. This approach aims to provide advanced treatment options for patients, potentially enhancing recovery times and outcomes. The foundation of Argonaut's research is rooted in pioneering work conducted at the University of Oxford.

Iota Sciences Ltd. is a company focused on developing tools and technologies that utilize fluid shaping technologies to enhance drug discovery processes. Founded in 2016 and headquartered in Oxford, United Kingdom, the company specializes in creating fluidic mu-wells specifically designed for cell biology applications. Through its innovative approach, Iota Sciences aims to provide unique capabilities that facilitate advancements in the understanding and manipulation of cellular processes, thereby accelerating research and development in the pharmaceutical sector.

Oxford Impedance Diagnostics Limited is a company based in Oxford, United Kingdom, that focuses on researching, designing, and marketing diagnostic tests specifically aimed at measuring clinical biomarkers. Founded in 2016, the company's products are intended to facilitate personalized medicine, enhance early risk detection, and improve the diagnosis and management of diseases. By providing innovative diagnostic solutions, Oxford Impedance Diagnostics seeks to reduce healthcare costs while improving patient outcomes.

Osler Diagnostics is a UK-based company focused on providing accessible and accurate health diagnostics. Founded in 2017 as a spin-off from the University of Oxford, the company has leveraged extensive research in portable diagnostic technologies, originally stemming from the development of the blood glucose sensor. Its flagship product, the Osler Origin, is a portable laboratory capable of delivering lab-quality diagnostics anytime and anywhere, enabling individuals to conduct tests for a variety of health biomarkers using just a drop of blood. This innovative approach aims to decentralize healthcare, making it easier for users to monitor their health and make informed decisions, ultimately supporting healthier and longer lives. Osler Diagnostics is headquartered in Oxford, UK, and aims to serve all major healthcare settings globally.

OMass Therapeutics is a biotechnology company based in Oxford, United Kingdom, that leverages structural mass spectrometry to discover protein-based novel medicines. The company develops a platform that provides access to native mass spectrometry and enables the study of complex protein assemblies and their interactions with biomolecules, allowing biotechnology and pharmaceutical clients to tackle challenging drug targets and biotherapeutics. Through a collaborative framework, OMass Therapeutics supports drug discovery efforts by applying its mass spectrometry technology to identify and characterize potential therapeutic candidates without requiring clients to establish in-house instrumentation and expertise.

Evox Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, that specializes in developing exosome-based therapeutics for the treatment of severe diseases with limited treatment options. Founded in 2016, the company focuses on harnessing and engineering extracellular vesicles, known as exosomes, to facilitate targeted delivery of nucleic acids and proteins. Evox's innovative platform allows for the modification of exosomes using advanced molecular engineering techniques, enabling effective drug delivery to specific organs, including the brain and central nervous system. By leveraging these natural delivery capabilities, Evox aims to overcome the limitations associated with conventional protein, antibody, and nucleic acid therapies, thereby creating novel therapeutic solutions that could significantly impact human health. The company is supported by a robust intellectual property portfolio and is positioned as a leader in this emerging therapeutic space.

DiffBlue is a software company that develops AI-powered automated testing and code automation tools. It automates coding tasks such as generating unit tests, bug fixing, refactoring, translating code between languages, and producing original code to meet specifications. Its automated testing software for Java creates fully autonomous unit tests, maintains regression tests, and provides insights into test coverage, code testability, complexity and dependencies. The technology uses reinforcement learning to write tests that compile, run, and detect bugs, reducing manual testing effort and accelerating software development. In addition to test generation, DiffBlue offers security testing capabilities to identify and fix exploits. DiffBlue originated as a spin-out of the University of Oxford's AI research group and is based in Oxford, United Kingdom.

Mind Foundry Limited, incorporated in 2015 and based in Oxford, United Kingdom, develops enterprise software that enables organizations to extract valuable insights from their data. As an Oxford University company founded by leading experts in artificial intelligence and machine learning, Mind Foundry focuses on creating Responsible AI solutions designed to address significant real-world challenges across various sectors, including insurance, infrastructure, and defense. Their AI platform leverages advanced machine learning and algorithmic modeling techniques to help organizations tackle issues such as insurance fraud detection and complex signal processing. By promoting the responsible and transparent use of AI, Mind Foundry aims to foster collaboration between humans and artificial intelligence to address pressing global problems.

Mixergy Ltd, founded in 2014 and headquartered in Cassington, United Kingdom, specializes in the development of innovative energy storage solutions, particularly hot water tanks. The company's technology is designed to enhance energy efficiency and support the integration of renewable energy sources, such as solar power and heat pumps. By providing a cost-effective means to store and utilize energy, Mixergy aims to facilitate grid balancing and optimize the use of renewable power, contributing to a more sustainable energy landscape.

Oxford Flow designs, manufactures, and supplies pressure control equipment, including gas and fluid pressure regulators, water PRVs, silencers, and pilots, serving water, gas, marine, oil and gas, process, power, building services, and specialty applications. The company develops small, light, and reliable conventional valves that simplify systems and ensure continual potable water supplies while meeting standards for water quality and leakage control. It combines academic and industry expertise to develop practical, rigorously tested solutions that perform under harsh conditions, aiming to reduce total cost of ownership and environmental impact while improving reliability and energy efficiency. Based in Oxford, United Kingdom.

Navenio Limited is a software technology company based in Oxford, United Kingdom, specializing in location-based services for indoor environments through mobile applications. Established in 2015, Navenio's innovative platform enhances indoor localization without the need for additional hardware, such as beacons or Wi-Fi. By utilizing advanced techniques like fingerprinting of the electromagnetic spectrum and indoor mapping, Navenio's solutions enable clients across various sectors, including retail, transportation, venues, and healthcare, to efficiently locate individuals and improve workforce productivity. The company's intelligent workforce solution automates processes based on established best practices, leading to significant enhancements in staff efficiency and operational workflows.

Bodle Technologies, established in 2015 and based in Begbroke, UK, specializes in advanced optoelectronic solutions for displays and smart windows. The company's core product is its proprietary SRD® technology, the world's first solid-state reflective display, which offers ultra-high resolution, vivid color, and video capability with zero energy use for static image storage. This bi-stable reflective display is ideal for wearables, near-eye, and projection-based displays, providing a more natural viewing experience, particularly in outdoor conditions. Additionally, Bodle Technologies develops security coatings that change color under various probing techniques, ensuring unbreakable security features in currencies, ID cards, and official documentation.